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Local funding would reduce waiting lists for cataracts
Editor—In her editorial on recruiting over›
seas doctors Rosen makes several important
points.1 We have been informed by the stra›
tegic health authority for Avon, Gloucester›
shire, and Wiltshire Strategic Health
Authority that many patients with cataracts
from Bristol Eye Hospital will have surgery
carried out at a local district general hospital
by a European team. Our nursing staff were
asked to provide information about the
number of “straightforward” cataract cases
on our waiting list. We expressed a
willingness to carry out this work ourselves
and were told by the Department of Health
that bids to carry out surgery to reduce
numbers on the waiting list would be
favourably received. Our highly competitive
bid was, however, turned down, without hav›
ing ever been looked at, despite having the
obvious advantages of audit, appraisal, and
continuity of care.
Bristol Eye Hospital has consistently
been at the forefront of innovation in
ophthalmology and cataract surgery in par›
ticular.2 3 We have met all our “Action on
Cataract” targets and increased our annual
cataract throughput by 60% in the past 18
months. We have repeatedly applied to do
more cataract surgery but have been unable
to do so because funding has not been
available.
It is difficult to maintain staff morale and
motivation when our local surgical teams
see funds that we have repeatedly requested
being spent on European surgeons carrying
out surgery at highly inflated rates, in the
knowledge that we shall be expected to look
after their complications and maintain our
own low complication rates, while operating
on the remaining complex cases and teach›
ing junior doctors. A small amount of extra
funding to employ optometrists in the
outpatient clinics to see suitable patients
could free surgeons to go to theatre and
carry out surgery to reduce the numbers on
the waiting list.4 This would cost a fraction of
the money that is earmarked for European
surgeons, but it lacks the dramatic impact
and headline grabbing potential.
Many of the staff working at our hospital
are from overseas, and some are from other
European countries. Given appropriate
funding we could also advertise for medical
staff who could work as fully integrated
members of a team here at the Bristol Eye
Hospital and thereby invest in and develop
the local service for years to come and not
just the short term.
Richard Harrad clinical director
Bristol Eye Hospital, Bristol BS1 2LX
r.a.harrad@bristol.ac.uk
On behalf of the 14 consultant ophthalmologists at
Bristol Eye Hospital.
Competing interests: The Bristol Eye Hospi›
tal wishes to be considered in open competition
for delivering this work.
1 Rosen R. Recruiting overseas doctors. BMJ 2002;325:
290›1. (10 August.)
2 Laidlaw DAH, Harrad RA, Hopper CD, Whitaker A,
Donovan JL, Brookes ST, et al. Randomised trial of the
effectiveness of second eye cataract surgery. Lancet
1998;352:925›9.
3 Frost NA, Hopper CD, Frankel SJ, Peters TJ, Durant JS,
Sparrow JM. The population requirement for cataract
extraction: a cross sectional study. Eye 2001;15:745›52.
4 Gray SF, Spry PG, Spencer IC, Brookes ST, Baker IA,
Peters TJ, et al. The Bristol shared care glaucoma study:
Outcome at follow›up at 2 years. Br J Ophthalmol
2000;84:456›63.
Outbreak of legionnaires’
disease in the United Kingdom
Vigilance must be eternal but balanced
Editor—Joseph underlines the paradox of
larger outbreaks of legionnaires’ disease
when understanding of causality is greater
than ever.1 She gives four explanations—loss
of vigilance in maintenance of water
systems, greater clinical awareness, better
surveillance, and easier diagnosis. She calls
for enhanced surveillance of both sporadic
disease and outbreaks and for greater
vigilance in control. Some lessons from
studies of legionnaires’ disease in Scotland
are pertinent to concerns fuelled by
outbreaks in England this summer.
In Glasgow a survey conducted after two
outbreaks, including the largest in the
United Kingdom up to 1984, showed up dif›
ficulties in maintaining an accurate register
of cooling towers, poor understanding
among some managers of premises about
the nature and location of cooling towers
and evaporative condensers, and breaches
of guidelines, usually on structural issues—
for example, control of the drift of cooling
towers rather than non›use of chemicals.2
The problems would have been even greater
without the publicity of the preceding
outbreaks. Breaches of guidelines on the
maintenance of hot water systems were also
of concern and constituted a hazard for
legionnaires’ disease.3
Apparently sporadic cases were often
part of mini›clusters.4 The conclusion,
anticipating that of Joseph, was that surveil›
lance needed strengthening and that solitary
cases needed investigation promptly for
potential early warning of an outbreak.
Information crucial to surveillance—
address, postcode, and date of onset—was
often missing from laboratory request
forms, which contribute to surveillance.
Clinicians must understand why such infor›
mation is needed so they are motivated to
provide it.
Studies of sporadic disease suggested
the sources of infection were similar to those
for outbreaks, for the epidemiological
patterns were similar, with proximity of the
home to a cooling tower being a risk factor.5
The costs of maintaining water
systems—both financially and in terms of
environmental contamination—are high, so
choices need to be made. Preliminary
economic analysis showed the emphasis
needs to be placed on maintenance of cool›
ing towers rather than domestic water
systems, but more work is needed on this.
Elimination of legionnaires’ disease is
not achievable, so vigilance combined with a
balanced response based on an understand›
ing of costs and benefits is required—neither
panic nor media pressure should drive
priorities. These lessons based on studies in
the 1980s remain relevant to understanding
and controlling the outbreaks that have
gripped the nation.
A longer version of this letter with a complete list of
references is available at bmj.com/cgi/eletters/325/
7360/347[25051.
Raj S Bhopal professor of public health
Public Health Sciences Section, Department of
Community Health Sciences, University of
Edinburgh, Edinburgh EH8 9AG
raj.bhopal@es.ac.uk
1 Joseph C. New outbreak of legionnaires' disease in the
United Kingdom. BMJ 2002;325:347›8. (17 August.)
2 Bhopal RS, Barr G. Maintenance of cooling towers follow›
ing two outbreaks of legionnaires' disease in a city.
Epidemiol Infect 1990;104:29›38.
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3 Bhopal RS, Barr G. Are hot and cold water systems main›
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answer. Health Hygiene 1991;12:159›65.
4 Bhopal RS, Diggle P, Rowlingson B. Pinpointing clusters of
apparently sporadic legionnaires’ disease. BMJ
1992;304:1022›7.
5 Bhopal RS, Fallon RJ, Buist EC, Black RJ, Urquart JD.
Proximity of the home to a cooling tower and the risk of
non›outbreak legionnaires’ disease. BMJ 1991;302:
378›83.
Official cleaning and disinfection
procedures must be adhered to
Editor—I have already reported a large
outbreak of legionnaires' disease in Japan,
but would like to add new information after
reading the editorial by Joseph.1 2
According to the latest official announce›
ment by Hyuga City, 294 (158 men and 136
women) became ill (29 confirmed and 265
probable cases), and six people (four men and
two women over 60 years old) died. All had
visited the same hot›spring resort in Hyuga
City and had been bathing in spas contami›
nated with Legionella pneumophila. The facility
was found not to have followed health minis›
try procedures for cleaning and disinfection
in spa and public bath facilities.
Most Japanese people are fond of
bathing in hot springs, but substandard
cleaning methods at spa and public bath
facilities nationwide are putting patrons at
risk from potentially lethal microorganisms.3
Scientists at the National Institute of
Infectious Diseases found amoebas at 151
(64%) of the 237 facilities they tested. In
2000 another large outbreak of legion›
naires’ disease occurred at a municipal pub›
lic bath in Ishioka City in Ibaraki Prefecture.
Three people died, and in 42 other people
the disease was diagnosed. The facility had
seldom exchanged recirculated hot water of
the public bath. The importance of follow›
ing ministry established cleaning and disin›
fection procedures to the letter should be
emphasised.
Hiroshi Kawane professor
Japanese Red Cross, Hiroshima College of Nursing,
1›2 Ajinadai›higashi, Hatsukaichi City, Hiroshima,
738›0052, Japan
kawane@jrchcn.ac.jp
1 Kawane H. Outbreak of legionnaires' disease in Japan.
bmj.com/cgi/eletters/325/7359/295/a#24993 (accessed
27 August 2002).
2 Joseph C. New outbreak of legionnaires' disease in the
United Kingdom. BMJ 2002;325:347›8. (17 August.)
3 Anonymous. Report: Onsen hygiene lacking. International
Herald Tribune/Asahi Shimbun 2002; Aug 16:22.
Extracorporeal membrane oxygenation
should be considered in severe cases
Editor—The sudden influx of around 92
patients, with 19 admissions to intensive
care, in the recent outbreak of legionella
pneumonia in Cumbria1 is a notable strain
on any health service.
The number of reported cases of
legionella infection in the United Kingdom
has increased steadily from 147 in 1993 to
226 in 1998.2 3 As Joseph says, legionnaires’
disease is often underdiagnosed and spo›
radic; only severe illness is detected and
reported. The most seriously affected
patients develop fulminant respiratory and
multisystem failure, and this is the main
cause of death for the 10›15% who die.1 4
We have used extracorporeal membrane
oxygenation in 16 adult patients with the
most severe form of legionella infection
between 1989 and 2001. Their modal ratio
of pulmonary artery oxygen content to frac›
tional inspired oxygen ratio before oxygena›
tion was 8.7 kPa (range 4.1›27.1 kPa), 13
were male, and their mean age was 43 years
(SD 10.6). They all received venovenous
extracorporeal membrane oxygenation for a
mean time of 258 hours (SD 235 hours).
Survival to hospital discharge was 69%,
with 11 of the 16 patients surviving at six
months. This is similar to the 66% survival
that we have reported for adult patients with
a variety of respiratory diagnoses.5
All extracorporeal membrane oxygena›
tion of adults in the United Kingdom now
falls within the remit of the CESAR trial
(www.cesar›trial.org). To be eligible for the
trial, patients must be aged between 18 and
65, have a Murray lung injury score of > 3.0
and a duration of high pressure or high oxy›
gen ventilation of < 7 days. We recommend
that any patients with severe legionella
infection who are deteriorating despite opti›
mal conventional intensive care should be
considered for the CESAR trial.
Nikki C Jones CESAR trial research fellow
Glenfield Hospital, Leicester LE3 9QP
nikki.jones@uhl›tr.nhs.uk
On behalf of G J Peek, N Roberts, C Harvey, A W
Sosnowski, H M Killer, R K Firmin (Glenfield Hospi›
tal); D Jenkins (Leicester General Hospital); and A
Truesdale, D Elbourne (London School of Hygiene
and Tropical Medicine).
1 Joseph C. New outbreak of legionnaires’ disease in the
United Kingdom. BMJ 2002;325:347›8. (17 August.)
2 Joseph CA, Dedman D, Birtles R, Watson JM, Bartlett CL.
Legionnaires’ disease surveillance: England and Wales
1993. Commun Dis Rep CDR Rev 1994;4:R109›11.
3 Joseph CA, Harrison TG, Ilijic›Car D, Bartlett CL. Legion›
naires’ disease surveillance: England and Wales 1998.Com›
mun Dis Public Health 1999;2:280›4.
4 Van Riemsdijk›van Overbeeke IC, van den Berg B. Severe
legionnaires’ disease requiring intensive care treatment.
Neth J Med 1996;49:196›201.
5 Peek GJ, Moore HM, Moore N, Sosnowski AW, Firmin RK.
Extracorporeal membrane oxygenation for adult respira›
tory failure. Chest 1997;112: 759›64.
Antenatal screening policies
for Down’s syndrome
Audit of Down’s syndrome screening is
not valid
Editor—Wellesley et al are unjustified in
their view that serum screening for Down’s
syndrome is not worth while.1 They ignore
evidence from previous studies that shows
the substantial advantage of serum screen›
ing over screening based on maternal age
alone.2–4 Their view is based on the results
from two districts, the only two out of the
eight where serum screening was routinely
offered (using the Double test).
In these two districts only 24% of
affected pregnancies (22 of the 91) were
detected antenatally by using serum screen›
ing, though the Double test has a detection
rate of 58% for a false positive rate of 5%.2
This could, at least in part, be due to a low
screening uptake (in which case the focus
should be on why this was so), but the uptake
of screening cannot be determined from the
paper. It could also be due to affected preg›
nancies that were positive on the serum test
and positive on other tests being classified as
positive under the other tests.
This problem arises because the detec›
tion rate used in this paper includes women
who declined screening (the performance of
screening tests, the uptake of screening, and
the uptake of amniocentesis should all be
reported separately). Methods of detection
(serum screening, scan, maternal age, etc)
were also tabulated in mutually exclusive
categories, which cannot be correct because
there will be pregnancies positive for Down’s
in two or more of these categories.
Wellesley et al compare screening results
across different districts. In doing so they
cannot (through lack of data) consider the
substantial variations between districts in
important factors that influence screening
such as maternal age, uptake of screening,
and use of ultrasonography. This problem is
solved by comparing different screening
methods in the same women—each woman
acting as her own control. There is no better
controlled study. Had they performed such
an analysis, as we suggested in response to
their earlier paper,5 they would have
confirmed the substantial advantage of
serum screening over age screening. Their
call for controlled trials is unjustified.
Wellesley et al are incorrect in saying
that the mathematical modelling carried out
by others to estimate the effect of serum
screening assumes that only 5% of pregnant
women were aged over 35. Such modelling
takes account of the maternal age distribu›
tion of the relevant population. The paper
does not specify the performance of
individual screening methods and does not
assess the benefits of one over another. It is
impossible to draw any valid conclusions
about the different methods of screening for
Down’s syndrome from it.
Nicholas J Wald professor
n.j.wald@qmul.ac.uk
Wayne Huttly screening manager
Allan K Hackshaw statistician
Wolfson Institute, Barts and the Royal London
School of Medicine and Dentistry, London
EC1M 6BQ
1 Wellesley D, Boyle T, Barber J, Howe DT. Retrospective
audit of different antenatal screening policies for Down’s
syndrome in eight district general hospitals in one health
region. BMJ 2002;325:15. (6 July.)
2 Haddow JE, Palomaki GE. Prenatal screening for Down
syndrome. In: Simpson JL, Elias S, eds. Essentials of prenatal
diagnosis. Edinburgh: Churchill Livingstone, 1993.
3 Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal
screening for Down’s syndrome. J Med Screen 1997;4:181›
247.
4 Spencer K. Second trimester prenatal screening for
Down’s syndrome using alpha›fetoprotein and free beta
hCG: a seven year review. Br J Obstet Gynaecol
1999;106:1287›93.
5 Wald NJ, Hackshaw AK, Huttly W. Serum screening
programmes are effective and safe. BMJ 2000;321:763›4.
Serum screening for Down’s syndrome is
better than age screening
Editor—Wellesley et al performed a retro›
spective audit of different policies of
antenatal Down’s syndrome screening in
eight hospital districts and concluded that
serum screening is not significantly better
Letters
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than age screening.1 This conclusion contra›
dicts the international experience,2 and can›
not be made from the reported data.
The activities in the different districts do
not reflect the policies stated—for example, a
policy, as in district A(1), in which serum
screening is offered without a routine
anomaly scan resulted in 11 out of 33
detected fetuses with Down’s syndrome
being found through an anomaly scan. Was
serum screening performed in these
patients? For each test we lack information
on the number of women tested and the
detection and screen positive rates for each
test. Without this, a comparison between dif›
ferent policies is impossible.
Wellesley et al make a mistake by not
correcting for the substantial death rate in
utero when calculating the total prevalence.
This is important when cases of Down’s syn›
drome may be detected as early as week 12
by chorionic villus sampling and as late as
week 24 from an anomaly scan.
Screening performance obviously
depends on the age distribution of the
examined population.3 The performance of
age screening can be calculated from the age
distributions of pregnant women and is cer›
tainly inferior to the performance of second
trimester serum screening, well documented
in prospective settings and in audit reports
from the United Kingdom.2 4 Modelling
studies have not presumed that 5% of preg›
nant women were older than 35 years, the
proportion, unsurprisingly, being 15%.5
Serum screening also reduces the rate of
invasive procedures in older women.4
Detection rates are partly based on cases
of Down’s syndrome in which mothers
refused prenatal testing. In district A among
women older than 35 years, nine babies with
Down’s syndrome out of 31 registered were
not detected antenatally because their
mothers refused the test and two because
serum screening failed. The detection rate is
therefore 20 detected cases from 22 total
cases=91% in the screened population and
not 65%. One dare not think of the poor
performance of the tests if a greater part of
the population had refused to participate in
the screening.
We hope that Wellesley et al will not
confuse the issue and delay the abandon›
ment of the obsolete age screening that is
causing an unacceptable number of unnec›
essary procedure related abortions of
healthy fetuses.
Michael Christiansen consultant
mic@ssi.dk
Severin Olesen Larsen biostatistician
Bent Nłrgaard›Pedersen professor
Department of Clinical Biochemistry, Statens
Serum Institut, 5 Artillerivej, DK›2300
Copenhagen S, Denmark
1 Wellesley D, Boyle T, Barber J, Howe DT. Retrospective
audit of different antenatal screening policies for Down’s
syndrome in eight district general hospitals in one health
region. BMJ 2002;325:15. (6 July.)
2 Cuckle H. Established markers in second trimester mater›
nal serum. Early Hum Dev 1996;47(suppl):S27›S29.
3 Larsen SO, Christiansen M, Nłrgaard›Pedersen B.
Calculation of roc curves in multidimensional likelihood
ratio based screening with Down’s syndrome as a special
case. J Med Screen 1998;5:57›62.
4 Edwards VM, Kennedy DM, Worthington DJ. Birmingham
Womens’s Hospital antenatal screening unit audit for Down’s
syndrome and neural tube defects. April 1997›March 1999. Bir›
mingham: Department of Clinical Biochemistry, Birming›
ham Women’s Hospital, 1999.
5 Christiansen M, Oxvig C, Wagner J, Qin QP, Nguyen TH,
Overgaard MT, et al. The proform of eosinophil major
basic protein: A new maternal serum marker for Down
syndrome. Prenat Diagn 1999;19:905›10.
Authors’ reply
Editor—Studies of screening policies for
Down’s syndrome provide answers for two
constituencies. The first is the individual
woman, who wishes to know, if she accepts it,
how likely the test is to detect an affected
fetus and how likely she is to be offered an
invasive test. The second is public health
policy makers, who must decide whether
introducing screening on a population wide
basis will achieve its goals of increasing the
detection rate of Down’s syndrome or
reducing the invasive procedure rate.
The studies to which Wald et al refer,
and their suggestion that women should act
as their own controls, answer the first
question, but not the second.
Christiansen et al correctly point out the
disparities between policies and practice.
The purpose of our study was to audit
screening in day to day practice, where
theory is disrupted by reality. A reality that
includes routine anomaly scanning, women
declining serum screening, older women
opting for the certainty of an invasive test
rather than screening, women declining
amniocentesis offered on the basis of their
age or serum screen result, etc. In this reality
women choose not to behave as expected,
hence screening programmes do not per›
form as predicted by theoretical models.
Wald et al correctly say that higher uptake
of screening would improve the detection
rate, but we should guard against coercing
women into having the test. Good counsel›
ling allows women to make a fully informed
choice, and this may lower uptake. Not every
mother agrees that it is desirable to identify
and terminate a fetus with Down’s syndrome.
Women offered prenatal screening found it
difficult to decline because they felt there was
an expectation they should participate.1
Another study of serum screening found that
only 38% of women having the blood test
understood they were being screened for
Down’s syndrome.2 In an ethnically diverse
population in the West Midlands only 35% of
Asian women with a high risk result opted for
amniocentesis.3 This implies that these
women did not understand the full implica›
tions of the screening test when the blood
sample was taken and that better counselling
would have lowered the uptake.
Our study shows that many factors extra›
neous to the screening test itself modify the
performance of a population programme,
with much greater effects than the small
differences achieved by different combina›
tions of serum analytes. We stand by our rec›
ommendation that screening programmes
should be tested in controlled trials.
David Howe consultant in fetomaternal medicine
Diana Wellesley associate specialist in clinical genetics
Princess Anne Hospital, Southampton SO16 5YA
1 Sjogren B, Uddenberg N. Decision making during the pre›
natal diagnostic procedure. A questionnaire and interview
study of 211 women participating in prenatal diagnosis.
Prenatal Diagnosis 1988;8:263›73.
2 Smith DK, Shaw RW, Marteau TM. Informed consent to
undergo serum screening for Down’s syndrome: the gap
between policy and practice. BMJ 1994;309:776›7.
3 Ford C, Moore AJ, Jordan PA, Bartlett WA, Wyldes MP,
Jones AF, et al. The value of screening for Down’s
syndrome in a socioeconomically deprived area with a
high ethnic population. Br J Obstet Gynaecol
1998;105:855›9.
Myopia
Confusing myopia with hypermetropia is
dangerous
Editor—The front cover of the BMJ on 18
May 2002 included an important error.
Above the headline, “Myopia: does reading
damage your eyes?” was a photograph of a
man and boy with hypermetropia, the
opposite condition. Hypermetropia, or long
sightedness, is corrected by spectacles with
convex (magnifying) lenses that make the
eyes appear larger, as shown in the
photograph. By contrast, myopia (near
sightedness) is corrected by concave lenses,
which make the eyes appear smaller.
Figure 1 of the article itself showed a girl
wearing myopic spectacles, though the
degree of myopia was only modest, about
− 2 D and certainly not the high (pathologi›
cal) myopia referred to in the legend.1
Indeed, the legends for figures 1 and 2 seem
to have been transposed.
Doctors need to be able to distinguish
hypermetropia from myopia. People with
hypermetropia are at increased risk of
developing acute angle closure glaucoma,
an unpleasant and sight threatening condi›
tion. In predisposed eyes acute angle closure
glaucoma may be induced by eye drops that
dilate the pupils or by drugs with pupil dilat›
ing side effects such as many antidepres›
sants.2 By contrast, iatrogenic angle closure
is almost unheard of in people with myopia.
We teach our students to look at a patient’s
spectacles as the first step in assessing the
risk of iatrogenic acute angle closure
glaucoma. For further practical help in
assessing this risk, non›ophthalmologists
should consult a general textbook.3
Martin Barnes Senior house officer in ophthalmology
Leicester Royal Infirmary, Leicester LE1 5WW
martin_barnes@doctors.org.uk
Tom Eke consultant ophthalmologist
Norfolk and Norwich University Hospital, Norwich
NR4 7UZ
1 Fredrick DR. Myopia. BMJ 2002;324:1195›9. (18 May.)
2 Hitchings R. Glaucoma. London: BMJ Publishing Group,
2000.
3 Chawla HB. Ophthalmology: a symptom based approach. 3rd
ed. Oxford: Butterworth Heinemann, 1999:33›4.
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Convergence might cause myopia
Editor—In his article on myopia Fredrick
said that most research into myopia has
been limited by its retrospective nature and
lack of control group and follow up.1 We
conducted a prospective, controlled, three
year follow up study of myopia and showed
direct evidence of myopic shift in students
reading and doing intensive near work com›
pared with children who were not attending
school, schoolchildren who did not read
much, and skilled manual labourers.2
Fredrick mentioned three possible
causes for the development of myopia:
retinal blur, accommodation, and familial
factors. A fourth possibility exists: conver›
gence. Convergence, rather than accommo›
dation, could be an important factor in
myopic progression.3–5
In their three year follow up study Pars›
sinen et al showed that neither the use of
bifocals nor avoiding the use of myopic
spectacles in reading slowed down myopic
progression.3 Parssinen and Lyyra found
more myopic progression in subjects need›
ing less accommodation than in those need›
ing more.4 They concluded that if accommo›
dation played a significant part in myopic
progression, reading with undercorrected
glasses or without glasses would probably
halt the process through a feedback
mechanism. In our study we observed a sig›
nificant axial length elongation during near
fixation both with and without cycloplegia
(with and without accommodation).5
These results do not support the
hypothesis of accommodation as a signifi›
cant cause of myopia. Rather, axial elonga›
tion during near focusing suggests that
convergence may be one factor inducing
myopia. Parssinen et al and Parssinen and
Lyyra thought that constant saccadic eye
movements during reading could cause
repeated pressure and stretch pulses on the
eye.
I think therefore that axial elongation,
which is a main cause of myopic progres›
sion, seems to result from the effect of
accommodative convergence rather than
accommodation itself. Much use of conver›
gence may be one of the contributing
factors in adult onset and adult progression
of myopia.
Huseyin Bayramlar associate professor in
ophthalmology
Inonu University, Turgut Özal Medical Centre,
44300, Malatya, Turkey
hbayramlar@yahoo.com
1 Fredrick DR. Myopia. BMJ 2002;324:1195›9. (18 May.)
2 Hepsen IF, Evereklioglu C, Bayramlar H. The effect of
reading and near›work on the development of myopia in
emmetropic boys: a prospective, controlled, three›year
follow›up study. Vision Res 2001;41:2511›20.
3 Parssinen O, Hemminki E, Klemetti A. Effect of spectacle
use and accommodation on myopic progression: final
results of a three›year randomized clinical trial among
schoolchildren. Br J Ophthalmol 1989;73:547›51.
4 Parssinen O, Lyyra AL. Myopia and myopic progression
among schoolchildren: a three›year follow›up study. Invest
Ophthalmol Vis Sci 1993;34:2794›802.
5 Bayramlar H, Cekic O, Hepsen IF. Does convergence, not
accommodation, cause axial›length elongation at near? A
biometric study in teens. Ophthalmic Res 1999;31:304›8.
Message about hormone
replacement therapy is unclear
Editor—Two contrasting leading articles
followed publication of the randomised trial
of the women’s health initiative study of hor›
mone replacement therapy.1 2
Stevenson and Whitehead in the BMJ
said that the increased risk of breast cancer
in the study was small, but they did not men›
tion that during the study 42% of women
taking active drug and 38% receiving
placebo stopped the assigned treatment.1
In contrast, Fletcher and Colditz
reported in JAMA that the intention to treat
analysis may have underestimated the true
effects. In addition, if the duration of
treatment is important as seems to be the
case with breast cancer and if compliance
decreases over time, then five year results
may have underestimated the long term
treatment effects.2
Stevenson and Whitehead deduced that
because the risk of breast cancer was not
appreciably increased in the first few years of
taking hormone replacement therapy,
women wishing to take short courses of this
form of hormone replacement should be
reassured. There must, however, be an inter›
val between applying an agent that increases
breast cancer development and the cancer
manifesting clinically, so the validity of their
deduction is open to question.
According to the BMJ editorial, long term
hormone replacement therapy could still be
considered for prevention of osteoporosis,
whereas the JAMA editorial finishes with the
definitive statement not to use oestrogen or
progestogen to prevent chronic disease.
Stevenson and Whitehead in the BMJ
say that the preliminary data of the effects of
hormone replacement in preventing
dementia are encouraging, but this is in
marked contrast to a review in the New Eng›
land Journal of Medicine last year. Although
several early observational studies show that
cognitive dysfunction or Alzheimer’s disease
is less likely to develop in women who take
oestrogen after the menopause, more recent
observational studies have not supported
this hypothesis.3 Furthermore, a recent
randomised trial did not show any benefit of
oestrogen as treatment for mild to moderate
Alzheimer’s disease,4 and the HERS study
did not show any benefit of hormone
replacement on cognitive function.5
Stevenson and Whitehead reported that
in the women’s health initiative study overall
mortality was not increased with treatment,
but the authors of the study make it clear
that as yet there are no meaningful data
from this study relating to use of hormone
replacement and mortality.
Conflicting and confusing views
expressed in major journals make it very
difficult for those of us who deal with
patients to put forward a coherent and con›
sistent message.
J Michael Dixon consultant surgeon
Academic Office, Edinburgh Breast Unit, Western
General Hospital, Edinburgh EH4 2XU
jmd@wght.demon.co.uk
1 Stevenson JC, Whitehead MI. Hormone replacement
therapy. BMJ 2002;325:113›4. (20 July.)
2 Fletcher SW, Colditz GA. Failure of estrogen plus proges›
tin therapy for prevention. JAMA 2002;288:366›8.
3 Manson JE, Martin KA. Postmenopausal hormone
replacement therapy. N Engl J Med 2001;345:34›40.
4 Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano
M, Doody R, et al. Estrogen replacement therapy for treat›
ment of mild to moderate Alzheimer disease: a
randomized controlled trial: Alzheimer’s disease coopera›
tive study. JAMA 2000;283:1007›15.
5 Grady D, Herrington D, Bittner V, Blumenthal R, Davidson
M, Hlatky M, Hsia J, et al. Cardiovascular disease outcomes
during 6.8 years of hormone therapy: heart and estrogen›
progestin replacement study follow›up (HERS II). JAMA
2002;288:49›57.
Authors’ refute careless talk
about ADP receptor antagonists
Editor—In January we reported the case of
a patient who developed acute arthritis after
taking ticlopidine.1 After reviewing the
literature and discovering another two case
reports of acute arthritis associated with the
use of a similar drug (clopidogrel),2 we
suggested that this class of ADP receptor
antagonists should be considered as a
potential cause of acute arthritis.
In April a letter by Green et al implied
that our report was “careless talk that may
cost lives,”3 which we refute.
Firstly, Green et al agree that the clinical
picture of our case is most likely an idiosyn›
cratic drug reaction, and yet they describe
our report as careless talk, which is rather
contradictory. They indicate that to confirm
this association the patient should be rechal›
lenged with the drug and the reaction docu›
mented. This is certainly true but not
practical in clinical practice. Many physi›
cians would consider it unethical to rechal›
lenge a patient with a drug that they are
highly suspicious caused an adverse reac›
tion. In addition, we do not believe that
patients would consent to such an experi›
ment.
Secondly, we strongly disagree with
Green et al that if these new drugs develop
an erroneous reputation for inducing
arthritis, the consequences may include not
providing optimal treatment.
Our job as a scientific medical commu›
nity is not to develop a good or an
erroneous reputation for a given drug but to
report facts and try to interpret them.
We were very careful in our concluding
sentence in the report to suggest a possible
association between ticlopidine and acute
arthritis rather than to confirm this
association.
Educated physicians do not build
their clinical practice on one or two case
reports. The fact that three patients
developed acute arthritis out of hundreds of
thousands of patients taking an ADP recep›
tor antagonist should not prevent doctors
from prescribing these extremely beneficial
drugs in cardiovascular disease. Similarly,
the 0.5›1.0% risk of intracranial bleeding
associated with thrombolysis did not pre›
vent doctors using it for acute myocardial
infarction.
Clinical practice is based on an assess›
ment of both the benefits and risks of drugs,
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and certainly the benefits of ADP receptor
antagonists are much greater than their
risks. This, however, does not deny the fact
that these drugs, like any drug, might have
serious side effects that doctors need to be
aware of.
In conclusion, we strongly disagree that
our report on the possible association of
ticlopidine with acute arthritis was careless
talk. On the contrary, we believe that
disregarding certain signs and symptoms, as
possible side effects of drugs would consti›
tute careless clinical practice.
Imad W Uthman associate professor
iuthman@aub.edu.lb
Habib A Dakik associate professor
Ibrahim Salti associate professor
Rachid Haidar associate professor
American University of Beirut Medical Centre, PO
Box 113›6044, Beirut 1103 2090, Lebanon
1 Dakik H, Salti I, Haidar R, Uthman I. Ticlopidine
associated with acute arthritis. BMJ 2002;324:27.
2 Garg A, Radvan J, Hopkinson N. Clopidogrel associated
with acute arthritis. BMJ 2000;320:483.
3 Green MJ, Iveson M, Crook R, Burrows N, Gough AKS.
Careless talk may cost lives in attributing adverse events to
ADP receptor antagonists. BMJ 2002;324:1039. (27 April.)
Prophylaxis for early onset
group B streptococcal sepsis is
not so effective in practice
Editor—Oddie and Embleton highlight the
dangers of and risk factors for early onset
group B streptococcal sepsis.1 They analysed
their data retrospectively and estimate that
most cases (78%) could have received effec›
tive antenatal or intrapartum prophylaxis
but accept that this interpretation might be
an overestimate.
This maternity unit recently introduced
a protocol for selective intrapartum prophy›
laxis against group B streptococcal infection
on the basis of recognised clinical risk
factors and subsequently audited our prac›
tice with respect to whether eligible women
received adequate prophylaxis or not.2 Over
an initial four week period 37 (10.3%) of 359
women were eligible for antibiotic prophy›
laxis, but only 12 (32%) of those eligible
received adequate prophylaxis. After minor
changes to the protocol and staff education,
a re›audit over a subsequent four week
period identified 49 (13%) of 378 women
eligible with 20 (42%) of those eligible
receiving adequate prophylaxis.3 This repre›
sents but a modest improvement.
This audit represents clinical practice in
a teaching hospital delivery suite. When
guidelines for prophylaxis against group B
streptococci are being designed, the differ›
ence between that which might be achieved
(78%1) and that which is achieved (32% to
42%3) needs to be recognised.
Philip Owen consultant obstetrician
Princess Royal Maternity Unit, Glasgow G31 2ER
Philipowen1@hotmail.com
1 Oddie S, Embleton ND Risk factors for early onset
neonatal group B streptococcal sepsis: case›control study.
BMJ 2002;325:308›11.
2 American Academy of Pediatrics Committee on Infectious
Diseases, Committee on Fetus and Newborn. Revised
guidelines for prevention of early›onset Group B strepto›
coccal (GBS) disease. Pediatrics 1997;99:489›96.
3 McCord N, Owen P, Powls A, Lunan B. A complete audit
cycle of intrapartum group B streptococcus prophylaxis.
Health Bull 2001;59:263›7.
Antibiotic prophylaxis after
CSF leaks lacks evidence base
Editor—Santarius et al in their Minerva arti›
cle perpetuate the unconfirmed and poten›
tially harmful myth that leaks of cerebro›
spinal fluid should be treated with antibiotic
prophylaxis.1 This lacks an evidence base, and
there are sound practical reasons why this
practice will not be effective.
This issue was addressed by a working
group of the British Society for Antimicrobial
Chemotherapy.2 The reasons put forward
were, firstly, that commonly used antibiotics
such as cephalosporins penetrate the non›
inflamed meninges poorly, and secondly, that
antibiotics are unlikely to eradicate potential
pathogens such as the pneumococci from the
upper respiratory tract. Conversely, treatment
may lead to colonisation with strains that are
resistant to antibiotics—for example, to
penicillin.3 These may then replace the more
easily treatable sensitive strains in any future
episodes of meningitis. Published reviews
have not shown that prophylactic treatment
is effective, and as such it should be
discouraged.
Resistance of microbes to antimicrobial
agents is rising throughout the world. Indis›
criminate use of these agents is often to
blame and is associated with bacterial super›
infections by organisms such as methicillin
resistant Staphylococcus aureus, antibiotic
associated diarrhoea, and drug specific side
effects.
Reduction in the use of antibiotics may
not reverse this trend in rising resistance but
will attenuate it as well as protecting patients
against drug side effects and healthcare sys›
tems against the financial costs. Prudent and
appropriate prescribing of antibiotics must
be the ultimate goal.
James R Greig consultant microbiologist
Derriford Hospital, Plymouth, Devon PL6 8DH
jjrgreig@yahoo.co.uk
1 Santarius T, Antoun NM, Kirollos RW. Minerva. BMJ
2002;325:554. (7 September.)
2 Antimicrobial prophylaxis in neurosurgery and after head
injury. Infection in Neurosurgery Working Party of the
British Society for Antimicrobial Chemotherapy Lancet
1994;344:1547›51.
3 Heikkinen T, Saeed KA, McCormick DP, Baldwin C,
Reisner BS, Chonmaitree T. A single intramuscular dose of
ceftriaxone changes nasopharyngeal bacterial flora in chil›
dren with acute otitis media. Acta Paediatr 2000;89:
1316›21.
Epidurals and backache: again?
Editor—Anaesthetists have reason to be
grateful to the BMJ for publishing yet
another trial, albeit a small one, showing that
epidural analgesia is not associated with
long term backache.1 On each occasion this
outcome seems to come as a surprise, so the
finding is worth repeating. The BMJ
published with alacrity several retrospective
studies that gave the erroneous result that
epidurals did cause backache,2 but it took
more persuading to publish prospective
studies with negative results,3 and it flatly
refused to publish one showing epidurals
were good for babies—good news is no news.
Readers may find it useful to know
that further clinical details of this same
study can be found in an earlier publication
by Howell et al, in which 184 women were
randomised to epidural and 185 to
non›epidural analgesia with primary out›
come measures as backache 3 and 12
months after delivery.4
The authors say that crossover between
treatment groups is inevitable in such trials.
Not so. Researchers in the University of
Texas Southwestern Medical Center, Dallas,
have published a series of trials in which a
total of 3727 women were randomised to
receive either epidural or systemic anal›
gesia. They made progressively more
successful efforts to improve analgesia in
the non›epidural arm, by the use of
generous patient controlled analgesia regi›
mens. In the latest study the crossover
amounted to only 3.1%.5
The cover picture relating to this article
is misleading. The epiduralist should be
wearing a mask and, in the United Kingdom,
would usually be wearing a gown (intuitively
safer, but not evidence based). The caption:
“Do epidurals cause long term backache?
No more than other forms of pain relief in
labour” is also misleading. It is not the pain
relief that causes backache—it is having a
baby.
Felicity Reynolds emeritus professor of obstetric
anaesthesia
St Thomas’s Hospital, London SE1 7EH
felicity.reynolds@btinternet.com
1 Howell CJ, Dean T, Luking L, Dziedzic K, Jones PW, Johan›
son RB. Randomised study of long term outcome after
epidural versus non›epidural analgesia during labour.BMJ
2002;325:357›9. (17 August.)
2 Russell R, Groves P, Taub N, O’Dowd J, Reynolds F. Assess›
ing long term backache after childbirth. BMJ
1993;306:1299›303.
3 Russell R, Dundas R, Reynolds F. Long term backache
after childbirth: prospective search for causative factors.
BMJ 1996;312:1384›8.
4 Howell CJ, Kidd C, Roberts W, Upton P, Jones PW, Johan›
son RB. A randomised controlled trial of epidural
compared with non›epidural analgesia in labour. Br J
Obstet Gynaecol 2001;108:27›33.
5 Sharma SK, Alexander JM, Messick G, Bloom SL, McIntire
DD, Wiley J, et al. A randomized trial of epidural analgesia
versus intravenous meperidine analgesia during labor in
nulliparous women. Anesthesiology 2002;96:546›51.
Growth hormone in growth
hormone deficiency
Ignore the evidence and keep going
wrong
Editor—We were surprised that in his
editorial to our paper Saenger challenged
our conclusions that most patients treated
for growth hormone deficiency do not have
this condition, and that controlled trials
should be organised to evaluate the long
term effects of growth hormone in most of
the patients currently treated.1 Saenger sup›
ports the use of an integrated approach to
diagnosing growth hormone deficiency and
the wider use of IGF›1 measurements, as
suggested by the Growth Hormone
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Research Society. However, his recent publi›
cations, as coauthor or senior author, do not
reflect his plea.2 3 This contradiction reflects
the widespread contrast between the recom›
mendations in consensus guidelines and
current practice or clinical research
protocols.
In the absence of a gold standard, how
can growth hormone deficiency be defined?
We propose using long term results of
treatment in comparison with spontaneous
outcome. The results of our observational
study indicate that most patients had no clear
benefit. Saenger argues that the patients in
our paper were not treated for long enough
and therefore do not provide long term
results of growth hormone treatment. He
contrasts our results with those reported by
Blethen et al in 121 patients from the
national cooperative growth study database,
who were treated for a mean of 6.2 years
compared with 3.2 years in our report.4
We included all patients who had started
treatment to calculate its mean duration,
whereas the 121 patients analysed represent
less than 1% of around 14 000 patients in
the national cooperative growth study. If we
had selected only the 1% of patients with the
longest treatment duration, our mean
treatment duration would have been 7.9
years. We thought that we had made it clear
in our paper that reports focusing on
patients with longer treatments give a biased
and overoptimistic view of the results. Obvi›
ously not clearly enough.
We agree with Saenger that you can draw
an analogy between the real estate business
and use of growth hormone: better location
in real estate and longer duration of growth
hormone treatment both mean higher costs.
However, a good location in real estate
generally results in a good long term
investment whereas the result of long term
growth hormone treatment is still debatable.
Jean›Claude Carel professor of paediatrics,
department of paediatric endocrinology
Emmanuel Ecosse statistician, department of
biostatistics
Joºl Coste professor, department of biostatistics
Groupe hospitalier Cochin›Saint Vincent de Paul
and FacultØ Cochin, UniversitØ Paris V, F›75014
Paris, France
1 Saenger P. Growth hormone in growth hormone
deficiency. BMJ 2002;325:58›9. (13 July.)
2 Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J, and
the Genentech ICSG. High dose recombinant human
growth hormone (GH) treatment of GH›deficient patients
in puberty increases near›final height: a randomized, multi›
center trial. J Clin Endocrinol Metab 2000;85:3653›60.
3 Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp
SF, Neuwirth RB, et al. A multicenter study of the efficacy
and safety of sustained release GH in the treatment of
naive pediatric patients with GH deficiency. J Clin Endocri›
nol Metab 2001;86:4700›6.
4 Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S,
Johanson A. Adult height in growth hormone (GH)›
deficient children treated with biosynthetic GH. The
Genentech Growth Study Group. J Clin Endocrinol Metab
1997;82:418›20.
Deficiency cannot be diagnosed solely on
the results of stimulation tests
Editor—We agree with Carel that many
children treated for idiopathic growth
hormone deficiency do not have this condi›
tion.1 We found that most children with idio›
pathic growth hormone deficiency had a
normal growth hormone response in stimu›
lation tests when retested at the attainment
of final height.2 Only patients with growth
hormone deficiency whose results on mag›
netic resonance imaging showed anatomical
abnormalities of the hypothalamic›pituitary
area had permanent growth hormone
deficiency. All the others had normal growth
hormone secretion at retesting.
Furthermore, we recently found that
among 33 prepubertal children with a
biochemical diagnosis of growth hormone
deficiency (a growth hormone response to
two stimulation tests < 10 ì/l), 28 had a
normal response when retested after two to
six months.3 Normalisation of the growth
hormone response to stimulation occurred
irrespective of the time interval from the first
evaluation and was not related to puberty
since none of our patients had entered
puberty before re›evaluation. This finding
does not support the concept of a transient
growth hormone secretory defect that
improves with the pubertal secretion of sex
steroids.
We and others have shown that concen›
trations of IGF›1 and IGFBP›3 are invari›
ably reduced in patients with severe,
unequivocal growth hormone deficiency.2 4
This indicates that subnormal concentra›
tions of IGF›1 and IGFBP›3 can be
considered diagnostic of growth hormone
deficiency, provided other causes of reduced
IGF›1 or IGFBP›3 such as malnutrition,
hypothyroidism, renal failure, and diabetes
are excluded. This observation, coupled with
the fact that IGF›1 concentrations do not
correlate with the results of growth hor›
mone stimulation tests,3 4 implies inadequate
assessment of growth hormone secretion
and emphasises the need for careful evalua›
tion of short children and eventual revision
of the current diagnostic criteria.
Although biochemical tests for growth
hormone secretion clearly distinguish chil›
dren with severe growth hormone defi›
ciency of pituitary origin, recognition of
more subtle forms of growth hormone
insufficiency still represents a diagnostic
dilemma. Idiopathic growth hormone defi›
ciency cannot be diagnosed solely on the
results of stimulation tests but requires
evaluation of multiple biochemical and
clinical or auxological variables.
We are convinced that patients with
pathological growth hormone responses to
provocative tests but normal results on mag›
netic resonance scans of the hypothalamic›
pituitary area should be re›evaluated and
followed up before a diagnosis of growth
hormone deficiency is firmly established.
Sandro Loche paediatric endocrinologist
Servizio di Endocrinologia Pediatrica, Ospedale
Regionale per le Microcitemie, Via Jenner, 09121
Cagliari, Italy
Sloche@mcweb.unica.it
Mohamad Maghnie paediatric endocrinologist
Clinica Pediatrica, Università di Pavia, Policlinico
San Matteo, IRCCS, Piazzale Golgi, 2, 27100 Pavia,
Italy
Marco Cappa paediatric endocrinologist
U O di Auxologia, Ospedale Bambino Gesø,
IRCCS, Via Torre di Palidoro, 00050 Palidoro,
Rome, Italy
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S, et al. Adult height after long term treatment with recom›
binant growth hormone for idiopathic growth hormone
deficiency: observational follow›up of the French popula›
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evaluation of the predictive criteria for permanent GHD in
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3 Loche S, Bizzarri C, Maghnie M, Faedda A, Tzialla C,
Autelli M, et al. Results of early re›evaluation of growth
hormone (GH) secretion in short children with apparent
GH deficiency. J Pediatr 2002;140:445›9.
4 Rosenfeld RG, Albertsson›Wikland K, Cassorla F, Frasier
SD, Hasegawa Y, Hinz RL, et al. Diagnostic controversy: the
diagnosis of childhood growth hormone deficiency
revisited. J Clin Endocrinol Metab 1995; 80:1532–40.
Local warming does help when
inserting cannulas
Editor—Lenhardt et al say that local warm›
ing improves the success rate for insertion of
peripheral cannulas.1 For people working in
a busy outpatient chemotherapy unit,
insertion of peripheral cannulas is a core
activity and can be extremely difficult,
particularly in patients who have had
repeated courses of chemotherapy.
Until recently we asked patients to
immerse their hands in warm water. This
manoeuvre was not always successful
because by the time patients had returned
to their chair and dried their hands, any
benefit was rapidly reduced. This led us to
investigate other forms of local warming
methods, which included proprietary
wheat filled bags. These can be readily pur›
chased in many gift and health shops. A
donation of a sack of wheat has enabled us
to provide a number of wheat filled bags
easily and cheaply. Removable cotton
covers have also been made to facilitate
laundering. Each bag measures approxi›
mately 150 cm×50 cm and is heated in the
microwave on high for 2 minutes. This
method also reduces the number of
attempts at cannulation.
Our own inhouse approach has provided
us with an effective low cost option and has
now been fully adopted. It may be that further
research is needed to compare other meth›
ods used within different clinical areas to pro›
vide data for evidence based practice.
Jeanette Beer clinical nurse specialist, chemotherapy
Department of Clinical Oncology, United
Lincolnshire Hospitals NHS Trust, Lincoln County
Hospital, Lincoln LN2 5QY
jeanette.beer@ulh.nhs.uk
1 Lenhardt R, Seybold T, Kimberger O, Stoiser B, Sessler DI.
Local warming and insertion of peripheral venous cannu›
las: single blinded prospective randomised controlled trial
and single blinded randomised crossover trial. BMJ
2002;325:409›10. (24 August.)
Supportive evidence is lacking
for report on animal studies
Editor—As Dobson notes, the House of
Lords Select Committee on Animals in Sci›
entific Procedures concluded that animal
experiments were necessary but that more
needs to be done to develop and promote
alternative methods.1
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Although it is clear that the committee
sought the views and opinions of a wide
range of experts, we were struck throughout
by the lack of published, peer reviewed
evidence to support one of its important
conclusions: “On balance, we are convinced
that experiments on animals have contrib›
uted greatly to scientific advances, both for
human medicine and for animal health.
Animal experimentation is a valuable
research method which has proved itself
over time” (page 22, para 4.8).2
We are not suggesting that the Lords did
not seek out such evidence (it is clear from
the transcripts published on the internet
that on many occasions they asked witnesses
to supply them with peer reviewed refer›
ences and reviews to support their claims
about the efficacy of animal experiments).3
Rather, we wish to draw attention to the
poverty and paucity of this evidence. Hardly
any systematic reviews, meta›analyses, or ret›
rospective, historical evaluations either sup›
port or refute the practice of using animals
as models of human disease. The Lords'
assertion of the value of animal experimen›
tation rests on the increase in effective
human treatments that have arisen at the
same time as the expansion of animal
experimentation. This correlation does not
mean that animals were necessary for the
development of these treatments.
The move in medicine to become more
evidence based needs to be replicated in
research. If uncertainty persists about a par›
ticular paradigm or method—in this case the
efficacy of using animals as models of
human disease—evidence needs to be
gathered so that claims about its efficacy can
be supported or refuted. If no evidence sup›
ports the use of a particular method and
only custom and practice sustain it, then that
method should be discarded. Currently ani›
mal tests are used as the gold standard by
which so called alternatives are judged, yet
virtually no evidence supports the use of the
animal tests themselves. In the few cases
where systematic reviews of animal experi›
ments have been conducted, serious doubts
have been raised about the methods used.4
Evaluating the practice of using animals
as models of human disease is fairly
straightforward and practicable when estab›
lished animal models of diseases exist.5 The
models should be evaluated retrospectively,
the key criterion being the productivity of
the animal model in terms of producing
treatments for humans.
Pandora Pound research fellow
Shah Ebrahim professor in epidemiology of ageing
Department of Social Medicine, University of
Bristol, Bristol BS8 2PR
1 Dobson, R. Lords support animal experiments but call for
alternatives. BMJ 2002;325:238.
2 House of Lords. Select Committee on Animals in Scientific Pro›
cedures. 16 July 2002. House of Lords. London: Stationery
Office, 2002.
3 House of Lords. Animals in scientific procedures. Available
at: www.publications.parliament.uk/pa/ld/ldanimal.htm
(accessed 9 October 2002).
4 Horn J, De Haan RJ, Vermeulen M, Luiten PG, Limburg M.
Nimodipine in animal model experiments of focal
cerebral ischemia: a systematic review. Stroke
2001;32:2433›8.
5 Shapiro KJ. Animal models of human psychology. Seattle:
Hogrefe and Huber, 1998.
New heart risk equations do
not affect existing guidelines
Editor—The paper by Nanchahal et al indi›
cates that substantially fewer men and women
without overt cardiovascular disease would be
eligible for drug treatment if the standard
1991 Framingham risk equation for coronary
heart disease risk that is used in the Joint Brit›
ish Cardiovascular Recommendations were
to be replaced with the 2000 model.1 2
This would be an important finding for
developers of cardiovascular guidelines and
budget holders if the newer risk equation
was substantially more accurate than the old
one. This seems unlikely, however, because
the new risk equation is based on a modest
number of end points (224 for men and 108
for women), and the equation for men
incorporates the same set of risk factors as
the 1991 equation.
What guideline developers need is a
comparison of the predictions of each risk
equation with observed incident cardiovas›
cular events, preferably over a range of
thresholds (an analysis of the characteristics
of receiver and operator). Published analyses
of receiver›operator characteristics show
that Framingham risk equations are only
modestly accurate against observed events
of coronary heart disease.3 4 We have also
shown that the 1991 and 2000 risk
equations have very similar discriminability
for coronary heart disease events in a New
Zealand cohort (unpublished data).
Fortunately for guideline developers, the
interesting findings reported in this paper
do not provide a good reason to abandon
the 1991 Framingham risk equations in
favour of the 2000 version. Cardiovascular
guidelines will need to be revised when bet›
ter risk equations become available.
Richard Milne associate professor
Divisions of Pharmacology and Community
Health, University of Auckland, PO Box 60315
Titirangi, 1007 Auckland, New Zealand
richard.milne@hoa.co.nz
1 Nanchahal K, Duncan JR, Durrington PN, Jackson RT.
Analysis of predicted coronary heart disease risk in
England based on Framingham study risk appraisal
models published in 1991 and 2000. BMJ 2002;325:194›5.
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Role of emotional capacity in
consent should be clarified
Editor—Case law does not clearly distin›
guish between intellectual and emotional
capacity. Sensky discussed the dilemma of
withdrawing treatment but missed an
opportunity to highlight the importance of
emotional capacity in decision making.1
What constitutes a mental disorder that
impairs capacity, making someone unable to
understand emotionally (as opposed to
intellectually) the personal relevance of
information and weigh it up? The judge’s
perspective cited by Sensky is this: refusal by
a mentally competent person to give
consent is an absolute right even if the
reason for this is irrational. But an irrational
reason for refusal of treatment suggests that
the ability to weigh evidence is impaired.
Value systems lie at the heart of mental
disorders. For example, people may become
depressed after having been made redundant
if they believe that their only value as a person
is determined by their productivity. That their
depression is in keeping with their value
system does not preclude doctors’ attempts to
prevent suicide and help them to overcome
the depression. Such is enshrined in mental
health law, but it also influences the determi›
nation of capacity in common law. In a case
heard by the Court of Appeal a needle
phobia was considered enough to render an
individual incapable of giving valid consent.2
In this case the patient probably held a value
that the experience of being injected by nee›
dles was unbearable. This patient would not
be considered as having a mental disorder by
people encountering her; yet in the context of
impending surgery she became so severely
anxious that she was considered incapable of
consenting to the procedure.
In the case reported by Sensky the
patient would similarly be considered not to
have a mental disorder until faced with a
situation that activated her value system. Her
value—continuing life in this manner is
worth less than death—has impaired her
ability to weigh the objective (intellectual)
evidence. She thereby expressed hopeless›
ness of living a life that she would consider
worth while. An alternative would be to work
with her to create a value system that would
enable her to consider her life worth while.
The role of emotionally held values and
beliefs in influencing an individual’s capacity
to give consent should be debated directly.
This issue could helpfully be resolved in the
drafting of the new Mental Health Act.
Other patients who are currently deemed to
have capacity (presumably intellectual)
despite the presence of psychosis or
overpowering affects related to adjustment
deserve to have their right to life protected
in keeping with the Human Rights Act 1998.
Steve Moorhead consultant in general psychiatry and
cognitive therapy
The Grange, Newcastle upon Tyne NE12 9PN
Doug Turkington senior lecturer in liaison psychiatry
Department of Psychiatry, University of Newcastle
upon Tyne, Leazes Wing, Royal Victoria Infirmary,
Newcastle upon Tyne NE1 4LP
1 Sensky T. Withdrawal of life sustaining treatment. BMJ
2002;325:175›6. (27 July.)
2 Re MB (Medical Treatment) [1997] 2 FLR 426.
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